மும்பை அடிப்படையிலானது க்ளேண்மர்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மும்பை அடிப்படையிலானது க்ளேண்மர்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மும்பை அடிப்படையிலானது க்ளேண்மர்க் Today - Breaking & Trending Today

Vaccines at 'Warp Speed': The Difference Between the US and India

The problem isn't that the Indian government is backing novel technologies even before they have been proven. It's that the Indian drug regulator is dysfunctional. ....

Johns Hopkins University , United States , Andhra Pradesh , Baylor College Of Medicine , Stephen Hahn , Gautam Gambhir , Madhav Thambisetty , Indian Expresswrote , Renu Swarup , K Vijayraghavan , Centre Suraksha , Department Of Biotechnology Renu Swarup , Indian Institute Of Science , Translational Health Science , Technology Institute , Serum Institute , Us Department Of Health , Human Services , National Expert Group On Vaccine Administration , Drug Administration , Johns Hopkins University School Of Medicine , Indian Council Of Medical Research , Bharatiya Janata Party , Department Of Biotechnology , Supreme Court , Operation Warp Speed ,

Hydroxychloroquine To Ivermectin, Indians Are Self-Medicating Against COVID And It Is Dangerous

Hydroxychloroquine To Ivermectin, Indians Are Self-Medicating Against COVID And It Is Dangerous
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.

Anusha Karra , Ny Prashanth Chandra , World Health Organization , Mumbai Based Glenmark , Gleneagles Global , Internal Medicine , Western Plains Hospital , Dodge City , அனுஷா கர்ரா , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , மும்பை அடிப்படையிலானது க்ளேண்மர்க் , க்ல்நேயேஜ்ல்ஸ் உலகளாவிய , உள் மருந்து , மேற்கு சமவெளி மருத்துவமனை , டாட்ஜ் நகரம் ,

COVID-19: FabiFlu replaces anti-diabetic drug to become top-selling pharma brand in India

COVID-19: FabiFlu replaces anti-diabetic drug to become top-selling pharma brand in India
Fabiflu mops up Rs 762 cr sales in the last 12 months, higher than the anti-diabetic drug, Glycomet-GP sales of Rs 564 crore.
(Image Source: ANI)
Updated: May 11, 2021, 12:58 PM IST
As India reels under a second and more deadly wave of the COVID-19 pandemic, the COVID drug FabiFlu sales witness a jump of 600% in the month of April.
Glenmark s FabiFlu, the generic version of Japanese anti-influenza drug Favipiravir is now the top-selling brand in the pharma retail market of India, data shows.
Sales of the drug which was running short of supply and saw constant SOS calls floating on social media went up by over 600% or six times, in one month. ....

Abbott Mixtard , Glenmark Fabiflu , Sanofi India , Mumbai Based Glenmark , சனோஃபி இந்தியா , மும்பை அடிப்படையிலானது க்ளேண்மர்க் ,

FabiFlu: Anti-Covid drug now top-selling pharma brand

MUMBAI: Call it the Covid effect. Anti-viral drug Favipiravir, used for Covid-19 treatment, has rocketed to the rank of the largest-selling pharma brand in April for the first time ever in the domestic retail market.
The drug, marketed by Mumbai-based Glenmark as Fabiflu, posted sales of Rs 352 crore in April alone, overtaking sales of drugs for lifestyle ailments such as diabetes, which have long dominated the market.
In April, Fabiflu overtook sales of other top-selling drugs being used in Covid-19 therapy, including health supplement Zincovit and pain-killer Dolo.
Fabiflu mops up Rs 762crore sales in last 12 months
During the pandemic, the top pecking order witnessed a change with Zincovit becoming the largestselling pharma brand in October last year, while others like Monocef, Dolo and Betadine grew at a strong clip this year. ....

Sun Pharma , Glenn Saldanha , Md Glenmark Pharmaceuticals , Mumbai Based Glenmark , Lasa Supergenerics , சூரியன் பார்மா , க்ளென் சால்தான் , மும்பை அடிப்படையிலானது க்ளேண்மர்க் ,

India's drug regulator has failed the pandemic stress test

By Dinesh Thakur Dec. 11, 2020Reprints
The approval of itolizumab, a drug made by Biocon, for treating Covid-19 in India has come under fire.
Aijaz Rahi/AP
The Covid-19 pandemic has served as a stress test for drug regulators across the world. India’s has failed.
Amid the desperate scrambles for therapeutics and vaccines to stem the havoc caused by the pandemic, drug regulators have had to resist tremendous political pressure to approve unproven therapies. Rick Bright, the former head of the Biomedical Advanced Research and Development Authority (BARDA), the federal agency that helps secure the U.S. from chemical, biological, radiological, nuclear, and emerging infectious disease threats, left his position, alleging in his whistleblower complaint that he faced political pressure to allow the distribution of hydroxychloroquine, an unproven drug for treating Covid-19 that had been championed by President Trump. ....

United States , Itolizumab Alzumab , Sundar Ramanan , Oxford Astrazeneca , Biomedical Advanced Research , World Health Organization , Municipal Corporation Of Bombay , Glenmark Pharmaceuticals , Development Authority , Central Drugs Standard Control Organization , United States Agency For International Development , Japan Fujifilm Group , Serum Institute Of India , National Taskforce Of The Government India , World Health , United States Agency , International Development , Drug Controller General , National Task Force , Cosmetics Act , Federal Register , Information Act , New Drugs , Clinical Trial Rules , Fujifilm Group , Mumbai Based Glenmark ,